Rispoval 3 also has a broad cross-neutralising ability against various current European strains of BVDV type 1 as measured by virus neutralization in vitro. Cross-neutralisation at a lower level is also demonstrated to BVDV type 2 strains. Clinical efficacy to BVDV type 2 strains has not been demonstrated.

The onset of immunity has been demonstrated from 3 weeks after the second vaccination against BRSV, PI3 and BVDV type 1. A duration of immunity has not been established for PI3.

No adverse effects, other than those already mentioned, have been observed following an overdose of ten times the modified live fraction (powder) and two times the inactivated fraction (liquid) of the vaccine.

No information is available on the safety and efficacy from the concurrent use of this vaccine with any other. It is therefore recommended that no other vaccines are administered within 14 days before or after vaccination with this product.